Current data confirm that the 6MWT , ISWT and ESWT are valid , reliable and responsive to change with some interventions .
However , results are sensitive to small changes in methodology .
Field walking tests are commonly employed to evaluate exercise capacity , assess prognosis and evaluate treatment response in chronic respiratory diseases .
In recent years , there has been a wealth of new literature pertinent to the conduct of the 6-min walk test ( 6MWT ) , and a growing evidence base describing the incremental and endurance shuttle walk tests ( ISWT and ESWT , respectively ) .
The aim of this document is to describe the st and ard operating procedures for the 6MWT , ISWT and ESWT , which can be consistently employed by clinicians and research ers .
Endurance shuttle walking test: responsiveness to salmeterol in COPD
Few studies have shown that the endurance shuttle walking test ( ESWT ) is responsive to treatment in patients with chronic obstructive pulmonary disease ( COPD ) . This exercise test needs to be further investigated because of its relevance for activity of daily living . The aim of the present study was to evaluate , in patients with COPD , the responsiveness of the ESWT in detecting improvement in walking performance after a single dose of salmeterol . In a r and omised , double-blind , placebo-controlled crossover trial , 20 patients with COPD performed two ESWT at 80 % of peak capacity 2.5 h after inhaling either a placebo or 50 µg of salmeterol  . Cardiorespiratory parameters were monitored during each walking test . Inspiratory capacities and Borg ratings for dyspnoea were obtained every other minute throughout the tests . Compared with placebo , salmeterol produced a significant change in lung function and a significant improvement in walking performance ( mean±sd difference in time : 117±20 s ; difference in distance : 160±277 m ) . At isotime ( the latest exercise time that was reached on both ESWT ) , a significant reduction in dyspnoea was observed after bronchodilation . Bronchodilation with salmeterol reduced dyspnoea during walking and improved walking capacity in patients with chronic obstructive pulmonary disease . These findings provide further support for the use of the endurance shuttle walking test as an evaluative tool in chronic obstructive pulmonary disease
Current data confirm that the 6MWT , ISWT and ESWT are valid , reliable and responsive to change with some interventions .
However , results are sensitive to small changes in methodology .
Field walking tests are commonly employed to evaluate exercise capacity , assess prognosis and evaluate treatment response in chronic respiratory diseases .
In recent years , there has been a wealth of new literature pertinent to the conduct of the 6-min walk test ( 6MWT ) , and a growing evidence base describing the incremental and endurance shuttle walk tests ( ISWT and ESWT , respectively ) .
The aim of this document is to describe the st and ard operating procedures for the 6MWT , ISWT and ESWT , which can be consistently employed by clinicians and research ers .